Holen Sie sich die Stockscreener-App
6.89
2.89%
-0.205
Vorhandelsmarkt:
7.19
0.30
+4.35%
Schlusskurs vom Vortag:
$7.095
Offen:
$7.02
24-Stunden-Volumen:
9,472
Relative Volume:
0.17
Marktkapitalisierung:
$22.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.52M
KGV:
-0.7084
EPS:
-9.7265
Netto-Cashflow:
$-31.51M
1W Leistung:
-6.64%
1M Leistung:
-20.44%
6M Leistung:
-13.88%
1J Leistung:
+1,398%
1-Tages-Spanne:
$6.88
$7.265
1-Wochen-Bereich:
$6.61
$7.88
52-Wochen-Spanne:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
6.89 | 22.10M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.82B | 606.42M | -1.28B | -997.58M | -6.403 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-10 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors - The Manila Times
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
PASG Surges 13% on Thin Volume — But No Catalyst to Back It - Bitget
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG) - The Globe and Mail
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
Passage Bio's 2025 net loss narrows - TradingView
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio management to present at two healthcare conferences - MSN
Passage Bio Management to Present at Two Healthcare Conferences - MyChesCo
Recap Report: Can Passage Bio Inc ride the EV waveQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Moving Averages: What is the earnings history of Passage Bio Inc2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Nasdaq Moves: Can Passage Bio Inc. reach all time highs this yearBear Alert & Expert Approved Trade Ideas - mfd.ru
Can Passage Bio Inc. stock hit record highs againInsider Buying & Advanced Technical Analysis Signals - mfd.ru
Passage Bio to Participate in Upcoming Investor Conferences - Caledonian Record
What downside risks could hit Goldman Sachs Equal Weight U.S. stockJuly 2025 Catalysts & Accurate Entry/Exit Alerts - mfd.ru
Can Passage Bio Inc. outperform in the next rallyJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growth2025 Earnings Impact & Weekly Chart Analysis and Guides - mfd.ru
Is Passage Bio Inc.’s ROIC above industry averageJuly 2025 Rallies & Entry Point Strategy Guides - mfd.ru
Why Putnam ETF Trust Putnam BioRevolution stock appeals to dividend investorsMarket Volume Summary & Low Risk Growth Stock Ideas - mfd.ru
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):